FCGR2A and neoplasm: FcγR-independent authentic CD40 agonists, as described in this study, however, are not useful when CD40 targeting is envisaged with the intention to stimulate FcγR functions, such as ADCC, ADCP, and CDC to kill tumor cells with high CD40 expression levels [44].